NCT03454750View on ClinicalTrials.gov

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Metastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT Positive
Interventions
DRUG

177Lu-PSMA

177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks

Trial Locations (1)

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER